Search Results
Department of Pediatrics, Navarra Hospital Complex, Pamplona, Spain
Navarra Institute for Health Research (IdisNA), Pamplona, Spain
Search for other papers by Teodoro Durá-Travé in
Google Scholar
PubMed
Search for other papers by Fidel Gallinas-Victoriano in
Google Scholar
PubMed
Search for other papers by María Malumbres-Chacon in
Google Scholar
PubMed
Search for other papers by Lotfi Ahmed-Mohamed in
Google Scholar
PubMed
Navarra Institute for Health Research (IdisNA), Pamplona, Spain
Search for other papers by María Jesús Chueca -Guindulain in
Google Scholar
PubMed
Navarra Institute for Health Research (IdisNA), Pamplona, Spain
Search for other papers by Sara Berrade-Zubiri in
Google Scholar
PubMed
sexual precocity have suppressed basal LH levels. That is, the presence of a high concentration of estradiol with low basal gonadotropins together with a rapid development of secondary sexual characteristics should compel to investigate for peripheral
Search for other papers by Sarmistha Banerjee in
Google Scholar
PubMed
Search for other papers by Allison M Hayes in
Google Scholar
PubMed
Search for other papers by Bernard H Shapiro in
Google Scholar
PubMed
Introduction Sexual dimorphisms of some dozen or more hormone- and drug-metabolizing constituent cytochromes P450 (CYPs) observed in rats, humans, and many other species examined ( 1 ) are defined by two characteristics. (i) Following puberty
Search for other papers by Britt J van Keulen in
Google Scholar
PubMed
Search for other papers by Conor V Dolan in
Google Scholar
PubMed
Search for other papers by Bibian van der Voorn in
Google Scholar
PubMed
Search for other papers by Ruth Andrew in
Google Scholar
PubMed
Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
Search for other papers by Brian R Walker in
Google Scholar
PubMed
Search for other papers by Hilleke Hulshoff Pol in
Google Scholar
PubMed
Search for other papers by Dorret I Boomsma in
Google Scholar
PubMed
Search for other papers by Joost Rotteveel in
Google Scholar
PubMed
Search for other papers by Martijn J J Finken in
Google Scholar
PubMed
committee of the Amsterdam UMC, location VUmc. Participants were physically examined by a researcher for pubertal stage at ages 9 and 12 years. The examination was based on secondary sexual characteristics according to Marshall and Tanner, that is, breast
Search for other papers by Amar Osmancevic in
Google Scholar
PubMed
Search for other papers by Kristin Ottarsdottir in
Google Scholar
PubMed
Search for other papers by Margareta Hellgren in
Google Scholar
PubMed
Search for other papers by Ulf Lindblad in
Google Scholar
PubMed
Search for other papers by Bledar Daka in
Google Scholar
PubMed
. ( https://doi.org/10.2164/jandrol.111.015065 ) 27 Tajar A Forti G O’Neill TW Lee DM Silman AJ Finn JD Bartfai G Boonen S Casanueva FF Giwercman A , Characteristics of secondary, primary, and compensated hypogonadism in aging men
Search for other papers by Silvia Ciancia in
Google Scholar
PubMed
Search for other papers by Vanessa Dubois in
Google Scholar
PubMed
Search for other papers by Martine Cools in
Google Scholar
PubMed
youth healthcare. Current guidelines recommend the use of GnRH analogs (GnRHa) to suppress puberty and prevent the development of secondary sexual characteristics. At ages 15–16 years, gender-affirming hormones (GAH) are usually added (non
Search for other papers by Yijun Tang in
Google Scholar
PubMed
Search for other papers by Yao Chen in
Google Scholar
PubMed
Search for other papers by Jiayi Wang in
Google Scholar
PubMed
Search for other papers by Qianwen Zhang in
Google Scholar
PubMed
Search for other papers by Yirou Wang in
Google Scholar
PubMed
Search for other papers by Yufei Xu in
Google Scholar
PubMed
Search for other papers by Xin Li in
Google Scholar
PubMed
Search for other papers by Jian Wang in
Google Scholar
PubMed
Search for other papers by Xiumin Wang in
Google Scholar
PubMed
secondary sexual characteristics during puberty, gynecomastia, and gender inconsistency between gonads and chromosomes showing 46,XY. Complete clinical data and genetic analysis results were evaluated. Subjects with any one of the following conditions were
Search for other papers by Sebastian Franik in
Google Scholar
PubMed
Search for other papers by Kathrin Fleischer in
Google Scholar
PubMed
Search for other papers by Barbara Kortmann in
Google Scholar
PubMed
Search for other papers by Nike M Stikkelbroeck in
Google Scholar
PubMed
Search for other papers by Kathleen D’Hauwers in
Google Scholar
PubMed
Search for other papers by Claire Bouvattier in
Google Scholar
PubMed
Search for other papers by Jolanta Slowikowska-Hilczer in
Google Scholar
PubMed
Search for other papers by Solange Grunenwald in
Google Scholar
PubMed
Search for other papers by Tim van de Grift in
Google Scholar
PubMed
Search for other papers by Audrey Cartault in
Google Scholar
PubMed
Search for other papers by Annette Richter-Unruh in
Google Scholar
PubMed
Search for other papers by Nicole Reisch in
Google Scholar
PubMed
Search for other papers by Ute Thyen in
Google Scholar
PubMed
Search for other papers by Joanna IntHout in
Google Scholar
PubMed
Search for other papers by Hedi L Claahsen-van der Grinten in
Google Scholar
PubMed
Search for other papers by the dsd-LIFE Group in
Google Scholar
PubMed
azoospermia is found in about 90% of adult men with KS ( 2 ). Other frequent clinical symptoms include gynecomastia, a low sexual drive, small testes and hypogonadism due to impaired testosterone production ( 3 , 4 ). KS is also associated with
Search for other papers by M Boering in
Google Scholar
PubMed
Isala, Department of Internal Medicine, Zwolle, The Netherlands
Search for other papers by P R van Dijk in
Google Scholar
PubMed
Langerhans Medical Research group, Zwolle, The Netherlands
Search for other papers by S J J Logtenberg in
Google Scholar
PubMed
Department of General Practice, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Search for other papers by K H Groenier in
Google Scholar
PubMed
Search for other papers by B H R Wolffenbuttel in
Google Scholar
PubMed
Search for other papers by R O B Gans in
Google Scholar
PubMed
Langerhans Medical Research group, Zwolle, The Netherlands
Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Search for other papers by N Kleefstra in
Google Scholar
PubMed
Isala, Department of Internal Medicine, Zwolle, The Netherlands
Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Search for other papers by H J G Bilo in
Google Scholar
PubMed
at the end of both treatment phases were used for analysis. Primary and secondary outcomes The primary outcome was the difference in SHBG concentrations between the CIPII and SC treatment phase. Secondary outcomes included the course of SHBG
Search for other papers by Athanasios Zervas in
Google Scholar
PubMed
National and Kapodistrian University of Athens Medical School, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece
Search for other papers by George Chrousos in
Google Scholar
PubMed
Search for other papers by Sarantis Livadas in
Google Scholar
PubMed
time of diagnosis. At the onset of puberty, many patients with PROP1 mutations also exhibit LH and FSH deficiency and fail to develop secondary sexual characteristics (possibly applicable to Dopey). The loss of gonadotropins may also present as an
Department of Endocrinology, St James’s Hospital, Dublin, Ireland
Search for other papers by Agnieszka Pazderska in
Google Scholar
PubMed
Search for other papers by Yaasir Mamoojee in
Google Scholar
PubMed
Search for other papers by Satish Artham in
Google Scholar
PubMed
Search for other papers by Margaret Miller in
Google Scholar
PubMed
Department of Endocrinology, University of Manchester, Manchester, UK
Search for other papers by Stephen G Ball in
Google Scholar
PubMed
Department of Paediatric Endocrinology & Diabetes, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK
Search for other papers by Tim Cheetham in
Google Scholar
PubMed
Endocrine Research Group, Institute of Genetic Medicine, University of Newcastle-upon-Tyne, Newcastle upon Tyne, UK
Search for other papers by Richard Quinton in
Google Scholar
PubMed
), the proportion of males with congenital hypogonadotrophic hypogonadism (CHH) rises steeply thereafter, eventually comprising the universality of cases by the third decade of life ( 2 ). Whereas both primary and secondary (CHH) ovarian insufficiencies